The signal, the score, and the play — in one place.

Purpose-built for Life Sciences commercial leaders. Not a dashboard. The operating layer between the signal and the decision.

Interface layer
Ask Marlow
Your AI analyst, fully briefed on every signal below
Foundation · always running
Intelligence Brief
Signal ingestion · synthesis · delivery · Tue + Fri
105+
competitors
970+
accounts
15000+
trials
LIVE
01

Intelligence Brief

FREE

Twice-weekly signal synthesis — filtered to what a commercial leader actually needs to act on.

  • Tuesday and Friday briefs delivered by email — curated from earnings calls, trial registrations, and macro demand signals
  • Each item: Signal → So What → The Play — with source attribution
  • Full coverage across all 105+ monitored competitors and 970+ accounts
Inbox
2 new
marlow@marlowiq.com
🔴 Lonza ADC expansion — capacity signal
Today 07:02 · Tue
marlow@marlowiq.com
⚠ Sartorius FY2025 recovery +4.2%
Today 07:02 · Tue
marlow@marlowiq.com
🌐 Macro: VC trough confirmed → demand lag
Today 07:02 · Tue
marlow@marlowiq.com
Agilent Q2 cautious — China/tariff
Fri 14:01 · Prev
54 briefs delivered · next: Tuesday 7am CT
The brief surfaces a signal — Top Opportunities ranks the account.
02

Top Opportunities

INSIGHTS

Signal-triggered GTM plays ranked by urgency — so you always know what to act on this week, this quarter, and what to watch.

  • Plays organized by urgency bucket: Weekly, Monthly, Quarterly, and Watch — driven by account press releases, pipeline events, and asset signals
  • Each opportunity surfaces the triggering signal, the account context, and the recommended commercial action
  • Updated continuously as new signals land — your GTM priority list reflects what happened this week, not last quarter's planning doc
RTW Plays · This Week
Weekly
Eli Lilly
Phase 3 enrollment opened
Monthly
AstraZeneca
dato-DXd ADC expansion
BioNTech
BNT122 Phase 2 readout
Quarterly
Novartis
PLUVICTO capacity signal
The account is ranked. Accounts has the full profile — trials, financials, signals.
03

Accounts

INSIGHTS

Deep profiles on 974 life sciences accounts — mIQ buying propensity score, clinical trial activity, pipeline signals, and financials in one view.

  • mIQ Score (0–100) for every account, recalculated weekly from CT.gov trial activity, pipeline stage, and financial posture — know who is ready to buy before your reps do
  • 15000+ active clinical trials tracked across the account set — phase transitions and breakthrough designations surface automatically in the account score
  • Full account profile: FDA actions, capacity events, leadership changes, and financial indicators updated from public filings
Eli Lilly LLY
GLP-1Biologics
94
TOP-TIER · ↑ +3
mIQ Score
Score breakdown
Financial Capacity22/25
R&D Commitment18/20
Pipeline Urgency21/25
Commercial Readiness17/20
Signal Velocity9/10
34 active trials · last signal: eloralintide Phase 3 recruiting opened
You have the account depth. Ask Marlow answers the follow-up in seconds.
04

Ask Marlow

PRO

Your Life Sciences intelligence analyst — on call, fully briefed, and already up to speed on your entire account and competitor universe.

  • AI analyst with your full platform context loaded: mIQ scores, mGS scores, trial data, competitor baselines, macro signals — answers are sourced, not hallucinated
  • Ask anything: which accounts are most likely to expand capacity, where a competitor is gaining share, how to frame your position for the board
  • Upload your own docs — call notes, positioning decks, field intel — and Marlow synthesizes internal and external context in the same answer
m
Ask Marlow
● Live context: 974 accounts · 108 competitors · 15000+ trials
Which accounts just hit a Phase 3 milestone this week?
Three this week:
Eli LillymIQ 94
Eloralintide Phase 3 — obesity
AstraZenecamIQ 89
dato-DXd NSCLC Phase 3
BioNTechmIQ 82
BNT122 pancreatic adjuvant
Sources: CT.gov · May 9, 2026
Ask anything about your market...

Also included

Every Insights and Pro subscription includes these alongside the core loop.

Competitor Intelligence

INSIGHTS

Strategic baselines and mGS growth scores for all 108 monitored competitors — updated every quarter.

Benchmarks

PRO

Peer financial comparison across the monitored set — op margin, R&D efficiency, and revenue growth in one terminal view.

GTM Diagnostic

PRO

AI-powered diagnosis of any company’s market position, ICP coverage, and GTM effectiveness — with four prioritized recommendation categories.

Live and updating
105+
competitors monitored
970+
accounts scored
15000+
active clinical trials tracked

Updated continuously. Synthesized weekly. Available now.